Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients with Heart Failure and Preserved Ejection Fraction:The VIP-HF study by van Veldhuisen, Dirk J et al.
 
 
 University of Groningen
Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients with Heart
Failure and Preserved Ejection Fraction
van Veldhuisen, Dirk J; van Woerden, Gijs; Gorter, Thomas M; van Empel, Vanessa P M;
Manintveld, Olivier C; Tieleman, Robert G; Maass, Alexander H; Vernooy, Kevin;
Westenbrink, B Daan; van Gelder, Isabelle C
Published in:
European Journal of Heart Failure
DOI:
10.1002/ejhf.1970
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Veldhuisen, D. J., van Woerden, G., Gorter, T. M., van Empel, V. P. M., Manintveld, O. C., Tieleman,
R. G., Maass, A. H., Vernooy, K., Westenbrink, B. D., van Gelder, I. C., & Rienstra, M. (2020). Ventricular
Tachyarrhythmia Detection by Implantable Loop Recording in Patients with Heart Failure and Preserved
Ejection Fraction: The VIP-HF study. European Journal of Heart Failure, (10), 1923-1929.
https://doi.org/10.1002/ejhf.1970
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
European Journal of Heart Failure (2020) RESEARCH ARTICLE
doi:10.1002/ejhf.1970
Ventricular tachyarrhythmia detection by
implantable loop recording in patients with
heart failure and preserved ejection fraction:
the VIP-HF study
Dirk J. van Veldhuisen1*, Gijs van Woerden1, Thomas M. Gorter1,
Vanessa P.M. van Empel2, Olivier C. Manintveld3, Robert G. Tieleman1,4,
Alexander H. Maass1, Kevin Vernooy2, B. Daan Westenbrink1,
Isabelle C. van Gelder1, and Michiel Rienstra1
1Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands; 2Department of Cardiology, Cardiovascular Research
Institute Maastricht (CARIM), Medical University Centre Maastricht, Maastricht, The Netherlands; 3Department of Cardiology, Erasmus Medical Centre Rotterdam, Rotterdam,
The Netherlands; and 4Department of Cardiology, Martini Hospital Groningen, Groningen, The Netherlands
Received 19 June 2020; revised 14 July 2020; accepted 15 July 2020
Aims The primary aim of the VIP-HF study was to examine the incidence of sustained ventricular tachyarrhythmias (VTs) in
heart failure (HF) with mid-range (HFmrEF) or preserved ejection fraction (HFpEF). Secondary aims were to examine
the incidence of non-sustained VTs, bradyarrhythmias, HF hospitalizations and mortality.
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Methods
and results
This was an investigator-initiated, prospective, multicentre, observational study of patients with HF and left ventricular
ejection fraction (LVEF) >40%. Patients underwent extensive phenotyping, after which an implantable loop recorder
was implanted. We enrolled 113 of the planned 250 patients [mean age 73± 8 years, 51% women, New York Heart
Association class II/III 54%/46%, median N-terminal pro B-type natriuretic peptide 1367 (710–2452) pg/mL and mean
LVEF 54± 6%; 75% had LVEF >50%]. Eighteen percent had non-sustained VTs and 37% had atrial fibrillation on Holter
monitoring. During a median follow-up of 657 (219–748) days, the primary endpoint of sustained VT was observed in
one patient. The incidence of the primary endpoint was 0.6 (95% confidence interval 0.2–3.5) per 100 person-years.
The incidence of the secondary endpoint of non-sustained VT was 11.5 (7.1–18.7) per 100 person-years. Five
patients developed bradyarrhythmias [3.2 (1.4–7.5) per 100 person-years], three were implanted with a pacemaker.
In total, 23 patients (20%) were hospitalized for HF [16.3 (10.9–24.4) per 100 person-years]. Fourteen patients
(12%) died [8.7 (5.2–14.7) per 100 person-years]; 10 due to cardiovascular causes, and four sudden deaths, one
with implantable loop recorder-confirmed bradyarrhythmias as terminal event, three others undetermined.
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Conclusion Despite the lower than expected number of included patients, the incidence of sustained VTs in HFmrEF/HFpEF was
low. Clinically relevant bradyarrhythmias were more often observed than expected.
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Keywords Heart failure with preserved ejection fraction • Heart failure with mid-range ejection fraction •
Ventricular tachyarrhythmias • Sudden death • Bradyarrhythmias
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Introduction
Heart failure (HF) with mid-range (HFmrEF) or preserved ejection
fraction (HFpEF) is an increasingly large medical and epidemiolog-
ical problem. At present, no pharmacological or device treatment
has convincingly been shown to improve outcome, and none of
these interventions is recommended for this indication in the cur-
rent European Society of Cardiology (ESC) HF guidelines.1,2 Sud-
den death is a common cause of death in all patients with HF.3
In the past, patients with HF with reduced ejection frac-
tion (HFrEF) often underwent diagnostic testing to determine
their arrhythmogenic risk profile and to examine the suscep-
tibility to develop lethal ventricular tachyarrhythmias. This was
mostly done by performing 24 h ambulatory Holter monitoring
and some reports indicated that that the presence of ventricu-
lar tachyarrhythmias in HFrEF was associated with sudden death
and all-cause mortality, whereas others did not.4–7 All studies
showed that the severity of left ventricular systolic dysfunction
was the dominant risk indicator for both sudden and all-cause
mortality in HFrEF. This has led to clear recommendations,
based on left ventricular ejection fraction (LVEF), for implantable
cardioverter-defibrillator (ICD) therapy to prevent sudden death
in HFrEF.1,8 Detection of ventricular tachyarrhythmias is not part
of the diagnostic work-up of patients with HFrEF anymore.1
In HFmrHF and HFpEF patients specifically, sudden death is one
of the most prominent modes of death.9,10 Studies have reported
incidences between 20–30% of all deaths.11–14 It is unknown,
however, whether ventricular tachyarrhythmias are the cause of
sudden death in patients with HFmrEF/HFpEF.
The primary objective of the Ventricular tachyarrhythmia detec-
tion by Implantable loop recording in Patients with Heart Failure
and preserved ejection fraction (VIP-HF) study was therefore to
examine the incidence of sustained ventricular tachyarrhythmias by
continuous rhythm recording using an implantable loop recorder
(ILR) during 2 years of follow-up in HFmrEF/HFpEF patients. Sec-
ondary objectives were to examine the incidence of non-sustained




The VIP-HF study was an investigator-initiated, prospective, mul-
ticentre, observational study conducted in The Netherlands
(ClinicalTrials.gov NCT01989299). The patients were included
between January 2015 and December 2019 in four centres in The
Netherlands. All patients provided written informed consent, and the
study was approved by the medical ethics committee in Groningen.
In addition, the present study was in concordance with the principles
outlined in the Declaration of Helsinki.
Study population
Patients were eligible for the VIP-HF study if they were aged >18 years,
had mild to moderate symptoms of HF [compatible with New York



















































































.. or emergency room visit for HF, or symptom relief with diuretics
within the previous 12 months. They could either be in sinus rhythm
or in atrial fibrillation (AF) and had elevated levels of natriuretic pep-
tides [i.e. an N-terminal pro B-type natriuretic peptide (NT-proBNP)
>300 pg/mL if in sinus rhythm, or >900 pg/mL if in AF]. The LVEF was
required to be >40% on echocardiography, and patients were required
to have echocardiographic evidence of functional and/or structural
alterations, including septal or posterior wall thickness ≥11 mm,
and/or left ventricular diastolic dysfunction (mean septal and lateral
e′ <9 cm/s, or E/e′ ≥13), and/or left atrial dilatation (left atrial volume
index ≥34 mL/m2).1 Key exclusion criteria included the presence of
an ICD or pacemaker, or an indication for ICD therapy according to
the ESC HF guidelines.1 In addition, patients with a life expectancy of
<1 year, as well as those with a myocardial infarction, percutaneous
intervention or coronary artery bypass graft within the last 3 months
were also excluded, as well as patients with complex congenital heart
disease. All patients were enrolled in the outpatient clinic.
Study procedures
At baseline, a comprehensive medical history, including a family his-
tory of premature sudden death, coronary artery disease, and HF
was obtained. In addition, patients underwent extensive phenotyp-
ing of HF, including echocardiography, 24 h ambulatory electrocardio-
graphic (ECG) Holter recording, and blood sampling for the analysis of
biomarkers, all using standard methods. Cardiac magnetic resonance
imaging (MRI) was performed using a 1.5 Tesla scanner, and images
were analysed off-line using dedicated software, as recently described
in detail.15 In addition, late gadolinium enhancement (LGE) images
were acquired 10 min after intravenous administration of 0.2 mmol/kg
gadolinium-based contrast agent (Dotarem, Gorinchem, The Nether-
lands, 0.2 mmol/kg; and Gadovist, Berlin, Germany, 0.2 mmol/kg).16,17
After baseline diagnostics were obtained, all study participants
received an Abbott® (Chicago, IL, USA) ILR, type Confirm® Model
DM2102 or Confirm Rx® model DM3500. The algorithm used for
rhythm monitoring was the same in ILR types, battery-lifetime was
minimal 2 years. The ILR was programmed with highest priority for
tachyarrhythmias. The tachyarrhythmia cut-off heart rate was the max-
imum heart rate on Holter monitoring plus 10 bpm, with a minimum of
150 bpm. All episodes lasting≥10 beats were stored. AF episodes >30 s
with heart rate below the tachyarrhythmia cut-off, based on irregular-
ity criteria, were stored separately as AF episodes. Bradyarrhythmias
and AF were programmed with lower priority. The bradyarrhythmia
cut-off rate was 30 bpm or asystole >3 s.
Typically for ILRs is that when the maximum storage capacity of the
ILR is reached, the oldest stored episode in its priority category is
overwritten by the new episode. To minimize the risk of ILR noise
capture, the sensitivity of the ILR was tested at every follow-up visit
using the R-wave amplitude, and the ILR was adjusted accordingly.
After ILR implantation, all patients were seen for ILR device inter-
rogation every 6 months, and yearly with the treating physician, with a
maximum of 2 years (based on the ILR battery life). All potentially clin-
ically relevant ILR events were communicated to the treating physician,
and potential treatment adjustments were left to the discretion of the
treating physician. Treatment of HF and associated comorbidities was
recommended according to the ESC HF guidelines.1
Endpoints
The primary endpoint was the incidence of sustained ventricular tach-
yarrhythmias in patients with HFmrEF/HFpEF. Sustained ventricular
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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tachyarrhythmia was defined as lasting >30 s or with haemody-
namic compromise. Secondary endpoints were the incidence of
non-sustained ventricular tachyarrhythmias, incidence of bradyarrhyth-
mias, HF hospitalizations, all-cause mortality and sudden death. An
endpoint adjudication committee, consisting of two experienced elec-
trophysiologists, assessed all ILR-documented events, and classified
tachyarrhythmias as ventricular tachyarrhythmias or AF. This commit-
tee was blinded to patient characteristics. If an ILR event was not
unanimously adjudicated, a third independent reviewer was consulted.
Statistical analysis
The study was designed to assess the incidence of sustained ventricular
tachyarrhythmias in patients with HFmrEF/HFpEF. A priori, we assumed
a mortality rate of 15% per year based on I-Preserve and CHARM, of
which one third would be due to sudden death, rendering a sudden
death rate of 5% per year.11,12 The assumption that every episode of
sustained ventricular tachyarrhythmias causes sudden death is not true.
Previously, the DEFINITE study demonstrated that appropriate ICD
shocks for sustained ventricular tachyarrhythmias occurred approxi-
mately twice as the number of sudden deaths in patients with HFrEF.18
Therefore we assumed that the incidence of sustained ventricular tach-
yarrhythmias would be twice as high as the expected sudden death rate,
i.e. 10% per year. During 2 years of follow-up, the expected incidence
rate of ventricular tachyarrhythmias would thus be 20% per 2 years. To
estimate a frequency of 20% sustained ventricular tachyarrhythmias in
a cohort of HFmrEF/HFpEF patients, with a confidence level of 95%,
the calculated sample size was 246, and therefore the aim of the study
was to include 250 patients. Due to the slower-than-expected enrol-
ment, the independent data safety monitoring board advised to stop
inclusion at 113 patients.
Data are presented as mean± standard deviation if (visually
inspected) distribution was normal, or median with interquartile
ranges if the distribution of data was non-normal. Categorical data are
presented as number (%). The incidence rates of the primary endpoint
of sustained ventricular tachyarrhythmias, and secondary endpoints
of non-sustained ventricular tachyarrhythmias, bradyarrhythmias, HF
hospitalizations and all-cause mortality with corresponding confidence
intervals were calculated using the package epiR in R. Differences
in continuous variables between groups were analysed using the
independent samples t-test or Wilcoxon rank test, depending on
the distribution. Differences in categorical variables between groups
were analysed using the Chi-squared test or Fisher’s exact test. The
association between non-sustained ventricular tachyarrhythmias on
Holter recording and all-cause mortality and the combined endpoint
of all-cause mortality and HF hospitalizations were assessed using a
Cox proportional hazard regression model. A Kaplan–Meier plot with
log-rank test was used to display the relation between Holter-detected
non-sustained ventricular tachyarrhythmias and all-cause mortality, and
the combined endpoint of all-cause mortality and HF hospitalizations.
Statistical analyses were performed using SPSS (version 23; Chicago,
IL, USA) and R (version 3.3.3; Vienna, Austria). Statistical significance
was considered achieved at a P-value <0.05.
Results
Patient characteristics
We enrolled a total of 113 patients, of whom 28 (25%) had HFmrEF



















































































.. age was 73± 8 years, 51% were women, and the patient character-
istics are depicted in Table 1. About half of the patients had mild
HF (NYHA functional class II), and of the others had moderate HF
(NYHA functional class III). Median NT-proBNP was markedly ele-
vated, and patients had a wide range of common comorbidities. On
Holter recording, 20 of the 113 patients (18%) had non-sustained
ventricular tachyarrhythmia with a median duration of 3 (3–5)
beats. Thirty-eight percent of patients had AF at baseline. Of the
113 patients, 105 underwent a cardiac MRI. In eight patients MRI
was not performed, mostly because of claustrophobia. Left ven-
tricular systolic and diastolic volumes were significantly larger in
patients with HFmrEF than in those with HFpEF (both P < 0.001)
(Table 2). The characteristics of the patients with non-sustained
ventricular tachyarrhythmias on Holter recording and those with-
out non-sustained ventricular tachyarrhythmias are depicted in
online supplementary Table SS1. Patients with non-sustained ven-
tricular tachyarrhythmias were more often men as compared to
those without non-sustained ventricular tachyarrhythmias (75%
vs. 43%, P = 0.009). In addition, the proportion of patients with
non-sustained ventricular tachyarrhythmias in NYHA functional
class II was higher (75% vs. 50%, P = 0.04), had a lower LVEF (51%
vs. 54%, P = 0.02), and more often had a high number of solitary
premature ventricular complexes on the baseline Holter record-
ing (45% vs. 20%, P = 0.02). On MRI, patients with non-sustained
ventricular tachyarrhythmias had larger left ventricular systolic and
diastolic volumes than patients without non-sustained ventricular
tachyarrhythmias (P = 0.001 and P = 0.002, respectively).
Sustained ventricular tachyarrhythmias
During ILR monitoring for a median of 657 (219–748) days, one
patient had a sustained ventricular tachyarrhythmia that deterio-
rated into ventricular fibrillation [incidence: 0.6 (95% confidence
interval 0.2–3.5) per 100 person-years] (Figure 1). This patient was
a 55-year-old man with LVEF 50% and extensive coronary artery
disease, for which he had undergone several interventions. He had
no ventricular tachyarrhythmias on his Holter, but earlier on his
ILR one relatively slow ventricular tachyarrhythmia of seven beats,
105 bpm was captured. After his cardiac arrest (after 1 year into
the study), he received an ICD, and his ILR was removed.
Non-sustained ventricular
tachyarrhythmias
Non-sustained ventricular tachyarrhythmias were observed on
ILR in 16 patients with a median of 19 (14–24) beats. These
non-sustained ventricular tachyarrhythmias on ILR were observed
after an average time of 7 months, two ventricular tachyarrhyth-
mias were observed >1 year after implantation. The incidence of
non-sustained ventricular tachyarrhythmias was 11.5 (7.1–18.7)
per 100 person-years.
Bradyarrhythmias
Clinically relevant bradyarrhythmias were seen in five patients, of
whom four had an indication for pacemaker therapy [3.2 (1.4–7.5)
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Patient characteristics of the study population
Total (n = 113) HFpEF (n = 85, 75%) HFmrEF (n = 28, 25%) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 72.6 ± 8.1 73.7 ± 8.0 69.2 ± 7.7 0.01
Women 58 (51%) 50 (59%) 8 (29%) 0.005
Body mass index (kg/m2) 29.7 ± 5.7 30.3 ± 5.7 28.3 ± 5.5 0.12
Comorbidities
Hypertension 89 (78%) 70 (82%) 19 (68%) 0.10
Previous myocardial infarction 23 (20%) 15 (18%) 8 (29%)
History of atrial fibrillation 64 (57%) 54 (64%) 10 (36%) 0.01
Diabetes mellitus 45 (40%) 35 (41%) 10 (36%) 0.6
Renal dysfunctiona 54 (48%) 41 (48%) 13 (46%) 0.9
COPD 21 (19%) 15 (18%) 6 (21%) 0.7
NYHA HF class 0.2
II 61 (54%) 43 (51%) 18 (64%)
III 52 (46%) 42 (49%) 10 (36%)
Previous HF hospitalization 48 (43%) 35 (41%) 13 (46%) 0.6
Baseline laboratory values
NT-proBNP (pg/mL) 1367 (710–2452) 1312 (687–2344) 1611 (744–2843) 0.9
Current medication
Beta-blockers 99 (88%) 24 (86%) 75 (88%) 0.7
ACEi/ARB 72 (64%) 52 (61%) 20 (71%) 0.3
MRA 42 (37%) 30 (35%) 12 (43%) 0.5
Diuretics 102 (90%) 76 (89%) 26 (93%) 0.6
Holter data
AF as basal rhythm 42 (37%) 35 (42%) 7 (25%) 0.12
Mean heart rate (bpm) 72 ±13 73 ±13 69 ±12 0.3
PVC ≥1000/24 h 27 (24%) 19 (23%) 8 (29%) 0.5
Non-sustained VT 20 (18%) 12 (15%) 8 (29%) 0.09
Echocardiography
LVEF (%) 54 ± 6 56 ± 5 45 ± 2 <0.001
LA volume index (mL/m2) 46 ±16 46 ±14 47 ± 21 0.8
LV mass index (g/m2) 102 ± 37 102 ± 39 103 ± 34 0.9
ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; HF, heart failure;
HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; LA, left atrial; LV, left ventricular; LVEF, left ventricular ejection
fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; PVC, premature ventricular
complex; VT, ventricular tachyarrhythmia.
aDefined as estimated glomerular filtration rate < 60 mL/min/1.73 m2.
per 100 person-years]. One patient developed dizziness, and had a
third-degree atrioventricular block, one patient had a near-collapse
and showed episodes of a slow ventricular escape rhythm (20 bpm),
and another patient had a serious collapse with a sinus arrest of 21 s
on ILR. All episodes were captured by the ILR.
Heart failure hospitalizations
and all-cause mortality
During the study, there were 23 HF hospitalizations [20%, 16.3
(10.9–24.4) per 100 person-years]. There were 14 deaths [12%,
incidence 8.7 (5.2–14.7) per 100 person-years], of which 10 due to
cardiovascular causes. Of the 10 cardiovascular deaths, four were
sudden deaths and the other six were due to progressive HF. Of
the four patients with sudden death, only two had non-sustained
ventricular tachyarrhythmias documented earlier on Holter/ILR. In
one of these four patients with sudden death, bradyarrhythmias


























. ventricular tachyarrhythmias. In the other three patients, the ILR
was not analysable, and the terminal phase rhythm was unknown.
There was no association between non-sustained ventricular tach-
yarrhythmias on Holter recording and all-cause mortality, or mor-
tality and HF hospitalizations combined (Figure 2).
Implantable loop recorder-related
adverse events
During the study, there were four ILR-related serious adverse
events. Two patients (1.8%) had mild pocket infections, with only
local inflammation and skin induration. In both patients, the ILR was
explanted and both patients were discharged the same day. In one
other patient, the ILR was removed at the request of the patient
because of irritation at the site after an elective coronary artery
bypass graft, with no signs of infection. In another patient the ILR
pocket was expanded, also with no signs of infection. Four more
patients had their ILR removed, three because of ICD or cardiac
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Cardiac magnetic resonance imaging characteristics
Totala (n = 105) HFpEF (n = 77) HFmrEF (n = 28) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Left ventricle
End-diastolic volume (mL/m2) 89 ± 25 84 ± 22 104 ± 26 <0.001
End-systolic volume (mL/m2) 43 ± 17 39 ±14 56 ±19 <0.001
Ejection fraction (%) 53 ± 8 54 ± 8 48 ± 9 0.001
Mass (g/m2) 57 ± 23 57 ± 23 59 ± 24 0.7
Right ventricle
End-diastolic volume (mL/m2) 81 ± 20 79 ±19 87 ± 21 0.1
End-systolic volume (mL/m2) 39 ± 15 38 ±15 42 ±15 0.3
Ejection fraction (%) 53 ± 10 52 ±11 53 ± 9 0.9
Ejection fraction <45% 25 (24%) 19 (25%) 6 (21%) 0.7
Late gadolinium enhancement (n = 91) (n = 64) (n = 27)
Positive (%) 30 (33%) 19 (30%) 11 (41%) 0.3
Ischaemic pattern (%) 18 (20%) 10 (16%) 8 (30%) 0.3
HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction.
aAvailable in 105 of 113 patients.
Figure 1 Bar graphs with 95% confidence intervals showing
the incidence of sustained and non-sustained ventricular tach-
yarrhythmias (VT).
resynchronization therapy with defibrillator implantation, and one
because of new breast cancer, most of them at patient’s request.
Discussion
First, the VIP-HF study had a lower than expected number of
patients, due to slow inclusion rates. Despite this, the main find-
ing of this study was the low incidence of sustained ventricular
tachyarrhythmias in patients with HFpEF/HFmrEF, 10 times lower
than anticipated. Second, clinically relevant bradyarrhythmias were
more often observed than expected. Lastly, the incidence of HF
hospitalizations and all-cause mortality was high, but no associa-
tion was seen with non-sustained ventricular tachyarrhythmia on
Holter monitoring.
Although it is increasingly recognized that non-cardiovascular
death is more common in patients with HFmrEF and HFpEF than
in HF patients with reduced LVEF, sudden death is still one of
the most common causes of death in this population.10,11,19 It is





















































.. if so, whether these are tachyarrhythmias or bradyarrhythmias.
No ILR or Holter data are available to date.19 To our knowledge,
the VIP-HF study is the first prospective study in HFmrEF/HFpEF
patients attempting to determine the incidence of ventricular
tachyarrhythmias and the rhythm directly before sudden death.
In the VIP-HF study, sustained ventricular tachyarrhythmias and
sudden death were uncommon. Prediction of increased risk of
sudden death in patients with HFmrEF/HFpEF has shown to be
difficult if not impossible.13,19,20 Attempts to create risk prediction
models in patients with LVEF >40% found age, male sex, history
of myocardial infarction, diabetes, presence of left bundle branch
block and NT-proBNP as risk indicators of sudden death.21,22
In addition, earlier studies suggest that the mortality risk may
be greater in ischaemic causes of HF, compared to HF due to
non-ischaemic causes.3 The majority of patients in VIP-HF did not
have a previous myocardial infarction, which may have led to a
lower sudden death rate.
In a recent paper focussing on renal patients, it was shown that
in contrast to traditional thinking, sudden death is often not caused
by ventricular tachyarrhythmias, but rather by bradyarrhythmias
followed by asystole.23 Interestingly, in VIP-HF, we also observed
a higher incidence of bradyarrhythmias than sustained ventricu-
lar tachyarrhythmias. In VIP-HF, five patients had significant brad-
yarrhythmia and/or asystole on ILR, of whom four had an indication
for pacemaker therapy, thereby potentially making it an important
clinical issue. One study examined the value of ILR in patients with
reduced LVEF and found clinical significant bradyarrhythmias in a
substantial proportion of patients.24 To our knowledge, no data on
the incidence of bradyarrhythmias in HFpEF are currently available.
Use of an ILR in the present study led to an increased number of
patients in whom non-sustained ventricular tachyarrhythmias was
detected (from 18% on baseline 24 h Holter monitoring to 27%).
No association between non-sustained ventricular tachyarrhyth-
mias on Holter monitoring and HF hospitalization or mortality was
observed. In a recent retrospective study of 85 HFpEF patients
with a pacemaker, 45% of patients had episodes of non-sustained
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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A B
Figure 2 Time-to-first event analysis of non-sustained ventricular tachycardia (nsVT) on Holter monitoring and all-cause mortality (A), and
composite of heart failure (HF) hospitalization and all-cause mortality (B).
ventricular tachyarrhythmias during 4 years of follow-up.25 In this
study also no association was found between non-sustained ven-
tricular tachyarrhythmias and mortality. HF patients with a pace-
maker are not comparable to those without a pacemaker since
their prognosis is more impaired.26
Study limitations
There are several limitations to this study. First, the number of
patients in the present study was limited, and smaller than orig-
inally planned, and conclusions should be cautiously interpreted.
Second, some inherent limitations come with ILR recording. The
battery life of ILR is limited, with a maximum of 2-year reliable
monitoring. In case ILR memory is full, ILRs start overwriting
already stored episodes. Establishing the cause of death with an ILR
may therefore be difficult, because the recording of the causative
episode may be replaced post-death with newer recordings of asys-
tole or noise. Absence of intracardiac leads, making distinction
between low-amplitude ventricular fibrillation and asystole difficult,
increases also the risk for noise capture.
Conclusions
Despite the lower than expected number of included patients,
the incidence of sustained ventricular tachyarrhythmias in HFm-
rEF/HFpEF was low. Clinically relevant bradyarrhythmias were
more often observed than expected.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Characteristics of patients with and without
non-sustained ventricular tachyarrhythmia on Holter monitoring.
Funding
The VIP-HF study (ClinicalTrials.gov identifier NCT01989299)























































.. Abbott-Netherlands to the University Medical Centre Groningen.
Abbott-Netherlands was neither involved in the conduction of the
study, nor in the writing of the manuscript.
Conflict of interest: none declared.
Appendix
VIP-HF principal investigator was D.J. van Veldhuisen (chair); and
co-chairs were M. Rienstra and I.C. van Gelder. Patients were
enrolled at the University Medical Centre Groningen (n = 90), The
Maastricht University Medical Centre (n = 18), the Erasmus Med-
ical Centre Rotterdam (n = 4), and the Medical Spectre Twente
Enschede (n = 1). Members of the Data Safety and Monitoring
Board were G.C.M. Linssen (cardiologist, Almelo), P.J.A.M. Brouw-
ers (Neurologist, Enschede), and H. ten Cate (Internist, Maas-
tricht). The Endpoint Committee consisted of R.G. Tieleman (Elec-
trophysiologist, Groningen) and A.H. Maass (Electrophysiologist,
Groningen).
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